Tivicay 50 mg film-coated tablets
Sponsors
Fundacion Seimc Gesida, Fundacion Seimc Gesida, Inserm, Chelsea And Westminster Hospital NHS Foundation Trust, Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal, Stichting Radboud universitair medisch centrum
Conditions
HIVHIV infectionHIV-1 infectionHIV-infectedMetabolic liver disease in HIV-infected peopleco-infected with the HIV-1 and HBV viruses
Phase 2
Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 antiviral treatment relief strategies, in patients co-infected with the HIV-1 and HBV viruses
RecruitingCTIS2023-508634-34-00
Start: 2025-05-14Target: 140Updated: 2025-10-20
Phase II, multicenter, open-label, randomized, controlled, open-label clinical trial to eliminate the latent reservoir of HIV-1 by administration of high doses of antiretroviral drugs.
RecruitingCTIS2024-513366-18-00
Start: 2025-04-07Target: 24Updated: 2024-09-09
Efficacy of doravirine + dolutegravir dual therapy in the context of antiretroviral therapy switch
Not yet recruitingCTIS2023-509751-14-03
Target: 50Updated: 2025-10-14
Phase 3
Phase 4
Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment regimen in HIV-infected patients with metabolic liver disease who maintain undetectable HIV viral load
CompletedCTIS2022-503110-23-00
Start: 2023-05-05End: 2025-07-07Target: 75Updated: 2023-08-28
Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)
CompletedCTIS2024-515487-31-00
End: 2025-12-12Target: 163Updated: 2024-10-22